Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2016, Article ID 5609121, 11 pages
http://dx.doi.org/10.1155/2016/5609121
Research Article

Peroxisome Proliferator-Activated Receptor α Reduces Endothelin-1-Caused Cardiomyocyte Hypertrophy by Inhibiting Nuclear Factor-κB and Adiponectin

1Division of Cardiology, Cheng-Hsin General Hospital, Taipei, Taiwan
2Institute of Clinical Medicine, Faculty of Medicine, Institute of Pharmacology, and Cardiovascular Research Centre, National Yang-Ming University, Taipei, Taiwan
3Department of Respiratory Therapy, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
4Graduate Institute of Integrated Medicine, College of Chinese Medicine, China Medical University, Taichung, Taiwan
5Department of Psychology, College of Medical and Health Science, Asia University, Taichung, Taiwan
6Department of Medical Research, Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan

Received 23 May 2016; Revised 19 August 2016; Accepted 15 September 2016

Academic Editor: Martina Fabris

Copyright © 2016 Hsu-Lung Jen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Tony, K. Meng, B. Wu et al., “MicroRNA-208a dysregulates apoptosis genes expression and promotes cardiomyocyte apoptosis during ischemia and its silencing improves cardiac function after myocardial infarction,” Mediators of Inflammation, vol. 2015, Article ID 479123, 11 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. C. Wojciechowska, E. Romuk, A. Tomasik et al., “Oxidative stress markers and C-reactive protein are related to severity of heart failure in patients with dilated cardiomyopathy,” Mediators of Inflammation, vol. 2014, Article ID 147040, 10 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. F. M. Drawnel, C. R. Archer, and H. L. Roderick, “The role of the paracrine/autocrine mediator endothelin-1 in regulation of cardiac contractility and growth,” British Journal of Pharmacology, vol. 168, no. 2, pp. 296–317, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Penna, R. Rastaldo, D. Mancardi et al., “Effect of endothelins on the cardiovascular system,” Journal of Cardiovascular Medicine, vol. 7, no. 9, pp. 645–652, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. T. A. Ajith and T. G. Jayakumar, “Peroxisome proliferator-activated receptors in cardiac energy metabolism and cardiovascular disease,” Clinical and Experimental Pharmacology and Physiology, vol. 43, no. 7, pp. 649–658, 2016. View at Publisher · View at Google Scholar
  6. E. Barlaka, E. Galatou, K. Mellidis, T. Ravingerova, and A. Lazou, “Role of pleiotropic properties of peroxisome proliferator-activated receptors in the heart: focus on the nonmetabolic effects in cardiac protection,” Cardiovascular Therapeutics, vol. 34, no. 1, pp. 37–48, 2016. View at Publisher · View at Google Scholar · View at Scopus
  7. Y. Irukayama-Tomobe, T. Miyauchi, Y. Kasuya, S. Sakai, K. Goto, and I. Yamaguchi, “Activation of peroxisome proliferator-activated receptor-α decreases endothelin-1-induced p38 mitogen-activated protein kinase activation in cardiomyocytes,” Journal of Cardiovascular Pharmacology, vol. 44, supplement 1, pp. S358–S361, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. Y. Irukayama-Tomobe, T. Miyauchi, S. Sakai et al., “Endothelin-1-induced cardiac hypertrophy is inhibited by activation of peroxisome proliferator-activated receptor-alpha partly via blockade of c-Jun NH2-terminal kinase pathway,” Circulation, vol. 109, no. 7, pp. 904–910, 2004. View at Publisher · View at Google Scholar
  9. K. Le, R. Li, S. Xu et al., “PPARα activation inhibits endothelin-1-induced cardiomyocyte hypertrophy by prevention of NFATc4 binding to GATA-4,” Archives of Biochemistry and Biophysics, vol. 518, no. 1, pp. 71–78, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Zou, K. Le, S. Xu et al., “Fenofibrate ameliorates cardiac hypertrophy by activation of peroxisome proliferator-activated receptor-α partly via preventing p65-NFκB binding to NFATc4,” Molecular and Cellular Endocrinology, vol. 370, no. 1-2, pp. 103–112, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Planavila, J. C. Laguna, and M. Vázquez-Carrera, “Atorvastatin improves peroxisome proliferator-activated receptor signaling in cardiac hypertrophy by preventing nuclear factor-κB activation,” Biochimica et Biophysica Acta—Molecular and Cell Biology of Lipids, vol. 1687, no. 1–3, pp. 76–83, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Xu and P. M. Vanhoutte, “Adiponectin and adipocyte fatty acid binding protein in the pathogenesis of cardiovascular disease,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 302, no. 6, pp. H1231–H1240, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. R. Shibata, N. Ouchi, M. Ito et al., “Adiponectin-mediated modulation of hypertrophic signals in the heart,” Nature Medicine, vol. 10, no. 12, pp. 1384–1389, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Fujita, N. Maeda, M. Sonoda et al., “Adiponectin protects against angiotensin II-induced cardiac fibrosis through activation of PPAR-α,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 5, pp. 863–870, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. Y.-M. Chang, B. K. Velmurugan, W.-W. Kuo et al., “Inhibitory effect of alpinate Oxyphyllae fructus extracts on Ang II-induced cardiac pathological remodeling-related pathways in H9c2 cardiomyoblast cells,” BioMedicine, vol. 3, no. 4, pp. 148–152, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. C.-L. Jao, S.-L. Huang, and K.-C. Hsu, “Angiotensin I-converting enzyme inhibitory peptides: inhibition mode, bioavailability, and antihypertensive effects,” BioMedicine, vol. 2, no. 4, pp. 130–136, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. Hattori, S. Hattori, and K. Kasai, “Globular adiponectin activates nuclear factor-κB in vascular endothelial cells, which in turn induces expression of proinflammatory and adhesion molecule genes,” Diabetes Care, vol. 29, no. 1, pp. 139–141, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. Y. Hattori, S. Hattori, K. Akimoto et al., “Globular adiponectin activates nuclear factor-κB and activating protein-1 and enhances angiotensin II-induced proliferation in cardiac fibroblasts,” Diabetes, vol. 56, no. 3, pp. 804–808, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Fruebis, T.-S. Tsao, S. Javorschi et al., “Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 4, pp. 2005–2010, 2001. View at Publisher · View at Google Scholar · View at Scopus
  20. Y. Qi, N. Takahashi, S. M. Hileman et al., “Adiponectin acts in the brain to decrease body weight,” Nature Medicine, vol. 10, no. 5, pp. 524–529, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. W.-H. Yin, Y.-H. Chen, J. Wei et al., “Associations between endothelin-1 and adiponectin in chronic heart failure,” Cardiology, vol. 118, no. 4, pp. 207–216, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. J.-W. Chen, F.-Y. Lin, Y.-H. Chen, T.-C. Wu, Y.-L. Chen, and S.-J. Lin, “Carvedilol inhibits tumor necrosis factor-α-induced endothelial transcription factor activation, adhesion molecule expression, and adhesiveness to human mononuclear cells,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 11, pp. 2075–2081, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. C.-S. Tsai, F.-Y. Lin, Y.-H. Chen et al., “Cilostazol attenuates MCP-1 and MMP-9 expression in vivo in LPS-administrated balloon-injured rabbit aorta and in vitro in LPS-treated monocytic THP-1 cells,” Journal of Cellular Biochemistry, vol. 103, no. 1, pp. 54–66, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Tenenbaum and E. Z. Fisman, “Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction,” Cardiovascular Diabetology, vol. 11, article 125, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. P. M. Barger, J. M. Brandt, T. C. Leone, C. J. Weinheimer, and D. P. Kelly, “Deactivation of peroxisome proliferator-activated receptor-α during cardiac hypertrophic growth,” The Journal of Clinical Investigation, vol. 105, no. 12, pp. 1723–1730, 2000. View at Publisher · View at Google Scholar · View at Scopus
  26. M. J. Goikoetxea, J. Beaumont, and J. Díez, “Peroxisome proliferator-activated receptor α and hypertensive heart disease,” Drugs, vol. 64, supplement 2, pp. 9–18, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. F. Liang, F. Wang, S. Zhang, and D. G. Gardner, “Peroxisome proliferator activated receptor (PPAR)α agonists inhibit hypertrophy of neonatal rat cardiac myocytes,” Endocrinology, vol. 144, no. 9, pp. 4187–4194, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. T. Ogata, T. Miyauchi, S. Sakai, Y. Irukayama-Tomobe, K. Goto, and I. Yamaguchi, “Stimulation of peroxisome-proliferator-activated receptor α (PPARα) attenuates cardiac fibrosis and endothelin-1 production in pressure-overloaded rat hearts,” Clinical Science, vol. 103, supplement 48, pp. 284S–288S, 2002. View at Google Scholar · View at Scopus
  29. E. L. Schiffrin, “Peroxisome proliferator-activated receptors and cardiovascular remodeling,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 288, no. 3, pp. H1037–H1043, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. P. J. H. Smeets, H. M. de Vogel-van den Bosch, P. H. M. Willemsen et al., “Transcriptomic analysis of PPARα-dependent alterations during cardiac hypertrophy,” Physiological Genomics, vol. 36, no. 1, pp. 15–23, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. P. J. H. Smeets, B. E. J. Teunissen, P. H. M. Willemsen et al., “Cardiac hypertrophy is enhanced in PPARα−/− mice in response to chronic pressure overload,” Cardiovascular Research, vol. 78, no. 1, pp. 79–89, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. W. P. Huang, W. H. Yin, J. W. Chen, H. L. Jen, M. S. Young, and S. J. Lin, “Fenofibrate attenuates endothelial monocyte adhesion in chronic heart failure: an in vitro study,” European Journal of Clinical Investigation, vol. 39, no. 9, pp. 775–783, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Ichihara, K. Obata, Y. Yamada et al., “Attenuation of cardiac dysfunction by a PPAR-α agonist is associated with down-regulation of redox-regulated transcription factors,” Journal of Molecular and Cellular Cardiology, vol. 41, no. 2, pp. 318–329, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Oyekan, “PPARs and their effects on the cardiovascular system,” Clinical and Experimental Hypertension, vol. 33, no. 5, pp. 287–293, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Shehzad, W. Iqbal, O. Shehzad, and Y. S. Lee, “Adiponectin: regulation of its production and its role in human diseases,” Hormones, vol. 11, no. 1, pp. 8–20, 2012. View at Google Scholar · View at Scopus
  36. C. M. Ghantous, Z. Azrak, S. Hanache, W. Abou-Kheir, and A. Zeidan, “Differential role of leptin and adiponectin in cardiovascular system,” International Journal of Endocrinology, vol. 2015, Article ID 534320, 13 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  37. B. J. Goldstein, R. G. Scalia, and X. L. Ma, “Protective vascular and myocardial effects of adiponectin,” Nature Clinical Practice Cardiovascular Medicine, vol. 6, no. 1, pp. 27–35, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Park and G. Sweeney, “Direct effects of adipokines on the heart: focus on adiponectin,” Heart Failure Reviews, vol. 18, no. 5, pp. 631–644, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. R. Shibata, N. Ouchi, K. X. Walsh, and T. Murohara, “Potential of adiponectin as a cardioprotective agent,” Future Cardiology, vol. 3, no. 6, pp. 647–656, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. C. Kistorp, J. Faber, S. Galatius et al., “Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure,” Circulation, vol. 112, no. 12, pp. 1756–1762, 2005. View at Publisher · View at Google Scholar · View at Scopus
  41. T. Tsutamoto, T. Tanaka, H. Sakai et al., “Total and high molecular weight adiponectin, haemodynamics, and mortality in patients with chronic heart failure,” European Heart Journal, vol. 28, no. 14, pp. 1723–1730, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. W.-H. Yin, J. Wei, W.-P. Huang, J.-W. Chen, M. S. Young, and S.-J. Lin, “Prognostic value of circulating adipokine levels and expressions of adipokines in the myocardium of patients with chronic heart failure,” Circulation Journal, vol. 76, no. 9, pp. 2139–2147, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. K. J. Clarke, Q. Zhong, D. D. Schwartz, E. S. Coleman, R. J. Kemppainen, and R. L. Judd, “Regulation of adiponectin secretion by endothelin-1,” Biochemical and Biophysical Research Communications, vol. 312, no. 4, pp. 945–949, 2003. View at Publisher · View at Google Scholar · View at Scopus
  44. C.-C. Juan, T.-Y. Chuang, C.-L. Chang, S.-W. Huang, and L.-T. Ho, “Endothelin-1 regulates adiponectin gene expression and secretion in 3T3-L1 adipocytes via distinct signaling pathways,” Endocrinology, vol. 148, no. 4, pp. 1835–1842, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. W.-L. Liao and F.-J. Tsai, “Personalized medicine: a paradigm shift in healthcare,” BioMedicine, vol. 3, no. 2, pp. 66–72, 2013. View at Publisher · View at Google Scholar · View at Scopus